Novo Nordisk's (NVO) said Friday that its investigative weight loss drug, amycretin, led to a body weight reduction of up to 22% in an early-stage trial. The maker of obesity drug Wegovy and diabetes ...
A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...
The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
Kelly Ripa ’s decision to stop drinking came with one surprise. While asking guest cohost Andy Cohen how his Dry January is going during the latest episode of Live With Kelly and Mark, the 54-year-old ...
Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback